ReviewFrontiers of medicine2017
Normoalbuminuric diabetic kidney disease.
Review in Frontiers of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- Clinical efficacy, safety, and cost of nine Chinese patent medicines combined with ACEI/ARB in the treatment of early diabetic kidney disease: A network meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Traditional Chinese medicine for the treatment of diabetic kidney disease: A study-level pooled analysis of 44 randomized controlled trials.Frontiers in pharmacology · 2022Pooled it
- Low-intensity extracorporeal shockwave therapy in patients with diabetic kidney disease: a matched cohort study.International urology and nephrology · 2025Trial
- Method for evaluating the human bioequivalence of acarbose based on pharmacodynamic parameters.The Journal of international medical research · 2020Trial
- Urinary biomarkers in the early diagnosis of diabetic kidney disease and diabetic retinopathy: A pilot study.Journal of medical biochemistry · 2026Article
- Serum Uric Acid to Creatinine Ratio as a Predictor of Normoalbuminuric DKD in T2DM with Normal Renal Function.International journal of general medicine · 2026Article
- Deconvolution of molecular mechanisms in di-n-butyl phthalate/mono-n-butyl phthalate induced diabetic kidney disease by integrated machine learning and molecular docking.BMC nephrology · 2025Article
- TGF-β: elusive target in diabetic kidney disease.Renal failure · 2025Review
- Germacrone Ameliorates Diabetic Kidney Disease by Activating TFEB to Promote Autophagy and Inhibit Inflammation.ACS omega · 2025Article
- Expression of urinary exosomal miR-136-5p in diabetic kidney disease and evaluation of its clinical diagnostic value.Scientific reports · 2025Article
- Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease-2025 Update.Nephrology (Carlton, Vic.) · 2025Article
- Social Inequalities in Hypertension, Dyslipidemia, and Cardiovascular Events Among Adults with Type 2 Diabetes: A Cross-Sectional Study from Saudi Arabia.Healthcare (Basel, Switzerland) · 2025Article
- Unraveling diabetic kidney disease: insights from single-cell RNA sequencing.International urology and nephrology · 2025Review
- Urinary L-FABP: A Novel Biomarker for Evaluating Diabetic Nephropathy Onset and Progression. A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Association between FT4/FT3 ratio and microalbuminuria in euthyroid patients with type 2 diabetes mellitus.Scientific reports · 2025Article
- Diabetic kidney disease: m6A modification as a marker of disease progression and subtype classification.Frontiers in medicine · 2025Article
- Shenyuan granules improve cellular senescence through Klotho-mediated p16/p21 signaling pathway in diabetic kidney disease.Frontiers in medicine · 2025Article
- The serum uric acid to creatinine ratio as a diagnostic biomarker for normoalbuminuric diabetic kidney disease.Frontiers in medicine · 2025Article
- AlteredExperimental biology and medicine (Maywood, N.J.) · 2025Article
- Research progress on the role of extracellular vesicles in the pathogenesis of diabetic kidney disease.Renal failure · 2024Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) is one of the primary causes of end-stage renal disease (ESRD). Early diagnosis is very important in preventing the development of DKD. Urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) are widely accepted as criteria for the diagnosis and clinical grading of DKD, and microalbuminuria has been recommended as the first clinical sign of DKD. The natural history of DKD has been divided into three stages: normoalbuminuria, microalbuminuria, and macroalbuminuria. However, this clinical paradigm has been questioned recently, as studies have shown that a portion of diabetes mellitus (DM) patients with normoalbuminuria have progressive renal insufficiency, referred to as normoalbuminuric diabetic kidney disease (NADKD) or nonalbuminuric diabetic nephropathy. Epidemiologic research has demonstrated that normoalbuminuric diabetic kidney disease is common, and the large number of NADKD patients suggests that the traditional paradigm needs to be shifted. Currently, the pathogenesis of NADKD remains unclear, but many clinical studies have identified some clinical and pathological features of NADKD. In addition, the long-term outcomes of NADKD patients remain controversial. In this article, we reviewed the latest studies addressing the pathogenesis, pathology, treatment and prevention of NADKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.